Addition of bevacizumab to cetuximab with or without irinotecan improves progression-free and overall survival durations

Author：

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1609, 2007-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates

By Lipton Allan

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 749-762

Informa Healthcare

Access to resources Recommend Favorite

Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

By Matulonis Ursula A. Oza Amit M. Ho Tony W. Ledermann Jonathan A.

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

Blackwell Publishing

Access to resources Recommend Favorite

Evaluating and Adjusting for Premature Censoring of Progression-Free Survival

By Rothmann Mark Koti Kallappa Lee Kyung Yul Lu Hong Laura Shen Yuan Li Zhang Jenny J. Jin Mei Zhou Haojin

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1091-1105

Taylor & Francis Ltd

Access to resources Recommend Favorite

Missing Data and Censoring in the Analysis of Progression-Free Survival in Oncology Clinical Trials

By Denne J. S. Stone A. M. Bailey-Iacona R. Chen T.-T.

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 951-970

Taylor & Francis Ltd

Access to resources Recommend Favorite

HIV-1 immunogen does not appear to improve HIV progression-free survival

Inpharma, Vol. 1, Iss. 1263, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite